Company: SCLXW
Filing Date: 2025-07-23
Form Type: 424B3
Source: 0001193125-25-163077
Chunk: 159

Company: Scilex Holding Co
Filing Date: 2025-07-23
Form: 424B3
Chunk 159
---
5 (the “Reverse Stock Split”) to certain investors (the
“Tranche B Holders”) pursuant to that certain Securities Purchase Agreement, dated October 7, 2024 (the “Tranche B SPA”), of which a warrant to purchase shares of Common Stock in the initial aggregate amount of
750,000 shares (on a pre-Reverse Stock Split basis, which is currently exercisable for 21,428 shares on a post-Reverse Stock Split basis) is held by the Holder (the “Existing Tranche B Warrant”);

WHEREAS, the Existing Tranche B Warrant was issued pursuant to the Company’s Registration
Statement on Form S-3 (File No. 333-276245) (the “Original Registration Statement”), which registration statement was subsequently converted to a
registration statement on Form S-1 to continue the registration of the shares of Common Stock issuable by the Company upon exercise of the Existing Tranche B Warrant (File
No. 333-280882) (the Original Registration Statement, as so continued, the “Continuation Registration Statement”) due to the Company’s ineligibility to use a Form S-3;

WHEREAS, in connection with certain transactions contemplated by the
Company, the Holder is concurrently providing its consent to such transactions and will exchange (the “Exchange”) the Existing Tranche B Warrants, effective as of and contingent upon the occurrence of the Closing (as defined below),
on the basis and subject to the terms and conditions set forth in this Agreement, and in reliance upon the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”), for a new Tranche B warrant to purchase 100,000 shares of Common Stock with an expiration date of October 8, 2029 and an exercise price of $40.00 per share, the form of which is attached hereto as Annex A(the
“New Tranche B Warrant”, and the shares to be issued upon exercise of the New Tranche B Warrant, the “New Warrant Shares”).

WHEREAS, concurrently herewith, the Company has also requested that each of the other Tranche B Holders (other than
Oramed) (the “Other Holders”) enter into an agreement in form and substance substantially similar to this Agreement (other than proportional adjustments based on different amounts of Tranche B Warrants held by such Other Holder and
reimbursement of legal fees) (